Better Therapeutics, Inc. · OTC:BTTX
Better Therapeutics — Investor Presentation (May 2022)
28 slides from Better Therapeutics's investor presentation, May 13, 2022
Slide 1: Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases
Exhibit 99.2 Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases MAY 2022
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTx” or the Company“) nor any of its respective affiliates nor any of its or their control persons, off
Slide 3: Executive Team
Executive Team David Kevin Mark Mark Kristin Thiago Deepti Jaggi, Perry Appelbaum Berman, MD Heinen Wynholds Oliveira PharmD Co-Founder, Co-Founder, Chief Chief Medical Chief Financial Chief Product Chief People Chief Strategy & Chairman Executive Officer Officer Officer Officer Officer Commercial O
Slide 4: Better Therapeutics is a prescription digital therapeutics company
Better Therapeutics is a prescription digital therapeutics (PDT) company founded on the hypothesis that we can create software to treat cardiometabolic diseases by changing the patient behaviors that are root causes. 4
Slide 5: Next Generation Therapeutics: Using Software Instead of Drugs
Next Generation Therapeutics: Using Software Instead of Drugs A Digital Therapeutics Platform – delivering novel cognitive behavioral therapy targeting the root causes of cardiometabolic diseases Demonstrated Results– clinically meaningful results in multiple trials for Type 2 Diabetes and Hypertens
Slide 6: We are spending more and more money to get worse and worse outcomes
We are spending more and more money to get worse and worse outcomes DIABETES HYPERTENSION US Healthcare Expenditures ($ in trillions) Americans Diagnosed with Hypertension (millions) US Healthcare Expenditures ($ in trillions) Americans Diagnosed with Diabetes (millions) $4 30 $4 110 $3 $3 22.5 82.5
Slide 7: Existing therapeutics treat symptoms but leave root causes untouched
Hypertension (high blood pressure) 70M people $30B Rx drug spending Type 2 Diabetes (high blood sugar) That’s because Root Causes 35M people Poor diet existing therapeutics $52B Rx drug spending Sedentary lifestyle Stress treat symptoms but Poor sleep Alcohol, Tobacco leave the common root causes un
Slide 8: Guidelines highlight behavior change, but physicians have no prescribable options
Current clinical guidelines highlight the importance of behavior change as the foundation of treatment, but physicians have no prescribable options Standard of Care guidelines emphasize the importance of behavior change in the management of disease Guidelines call for digital solutions to facilitate
Slide 9: Traditional CBT is effective but neither scalable nor affordable
Traditional Cognitive Behavioral Therapy (CBT) is effective at addressing the behavioral root causes of cardiometabolic diseases but is neither scalable nor affordable Not Standardized “The results of this study show that PC-CBT lifestyle Treatment plans to treat cardiometabolic diseases with interv
Slide 10: We created nutritional CBT to treat root causes of cardiometabolic diseases
We created nutritional CBT to treat the root causes of cardiometabolic diseases and can deliver it digitally to make it accessible, affordable and scalable Targets eating Designed for Enhances and related cognitive primary care behaviors restructuring Designed to work within the existing framework o
Slide 11: We deliver nutritional CBT using a mobile app prescribed by a physician
We deliver nutritional CBT using a mobile app prescribed by a physician Nutritional CBT is delivered via weekly therapy lessons, skill-building modules, and goal-setting. A treatment algorithm tailors treatment to each individual patient. Feedback is provided using a treatment score, rewards, and pr
Slide 12: BetterCare software platform for providers
BetterCare is a software platform that allows providers to monitor patients during treatment and intervene when necessary • Visualize treatment progress from prescription to refill • Monitor activity and biometrics • Identify patients at risk • Enable early intervention 12
Slide 13: Medication review recommendation using patient generated data
RECOMMENDATION: Medication Review By using patient generated Denise Ann’s fasting blood sugar has averaged data, providers can make 104 mg/dL for 3 weeks. It may be time to schedule an appointment to review medications. more informed clinical De • Metformin 2000 mg PO per day decisions and intervene
Slide 14: Pipeline of PDT products using nCBT
We are advancing a pipeline of PDT products using nCBT to treat multiple cardiometabolic diseases Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Pivotal (BT-001) FDA Review Type 2 Diabetes Pilot Pivotal (BT-002) Hypertension Pilot Pivotal (BT-003) Hyp
Slide 15: Pivotal trial results: BT-001 improves A1c vs. control
Primary Endpoint (Day 90) Secondary Endpoint (Day 180) First in class, pivotal BT-001 arm (n=296) improves A1c by 0.4% vs. Changes in A1c between BT-001 and RCT demonstrating Standard of Care Control (n=312) in Intent-to- Control group efficacy in type 2 treat (ITT) Analysis, p = 0.00003 Changes in
Slide 16: Primary endpoint data at 90 days
Control 0.2 0.13% Control 0.1 0.06% Primary endpoint data at 90 days demonstrated clinically n=244 n=312 0 n=296 n=156 meaningful response with no serious adverse events -0.1 Glycemic improvements highly statistically -0.2 significant. Important study context: COVID, seasonal impact, inconsistent ti
Slide 17: Greater engagement linked to greater A1c improvement
Greater engagement in nCBT linked to greater improvement in A1c, indicating a clear dose-response Low Completion of Moderate Completion of High Completion of Therapy Lessons Therapy Lessons Therapy Lessons < 6 lessons 6-11 lessons >11 lessons 0 n=92 n=99 n=102 -0.1 -0.2 -0.25% -0.3 -0.32% -0.4 -0.5
Slide 18: Patient engagement and retention exceed consumer health apps
Average minutes / day spent in app 6.8 During the first 90 days of use, patient Average number of Lessons engagement and 8.3 completed (out of a possible 13) persistence exceed that of consumer health & wellness apps* 90 day retention compared to 36% % for consumer healthcare apps* 94 *Apptentive |
Slide 19: Potential claims based on primary and anticipated secondary endpoint data
Potential claims based on primary endpoint and anticipated secondary endpoint data Indications for Use Clinical Claims BT-001 is a prescription-only software BT-001 is designed to help patients with type 2 diabetes improve glycemic control by lowering A1c program intended to help adult patients with
Slide 20: Patient journey and incremental cost of type 2 diabetes treatment
My doctor is talking about I’ve got time to When my symptoms I’m exhausted. I can’t sleep or seem to “ “ “ “ insulin…I’m scared. I feel change… this won’t started – dizziness, blurred think straight. I’m feeling worse like once you hit insulin you impact my life.” vision, getting up to go to and now
Slide 21: Our value story is compelling to payers
Our value story is compelling to payers and we are substantiating it with robust evidence Type 2 diabetes is among the largest expenses categories for payers (#1 in Medicare and VA; #5 in commercial insurance); patients with T2D cost Disease burden an additional $11k per year than individuals withou
Slide 22: Real-world evidence from a 1,000 participant study
Real-world evidence from a 1,000 participant randomized, controlled, multi-site study will inform our understanding of durability, impact on costs and medication use 3-Month Data 6-Month Data 9-Month Data First Patient In (250 pts) (750 pts) (1000 pts) Q4-23 Oct-21 Q4-22 Q2-23 BT-001 Study Size Dura
Slide 23: Initial focus on patients who would otherwise step to insulin
If authorized by FDA, we will focus on patients who would otherwise step to insulin or other costly injectables at launch Diagnosed with type 2 diabetes 25M Diabetes population Not on mealtime insulin 19M Commercial/Medicare 16M <80 years old 14M Uncontrolled 8M Step to insulin 2.6M / year 23
Slide 24: Pricing relative to incremental healthcare costs per patient
Incremental Healthcare Costs per patient, per year We intend to price in Insulin order to provide compelling value to payers and maximize GLP-1 access by minimizing controls such as prior authorizations and BT-001 step edits $0 $1,000 $2,000 $3,000 $4,000 $5,000 $6,000 $7,000 $8,000 $9,000 24 Source
Slide 25: Launch focus on coverage, physicians and sales team
4,000 Primary Care Physicians At launch, we will focus & Endocrinologists on securing coverage from regionally 8-10 $800-1,000 dominant, early adopting Market Access WAC per 90 day Rx FTEs commercial insurers and health systems. 2.6MM A team of 20-40 FTEs will engage Patients Per Year and educate ap
Slide 26: Value creating milestones over the next 18 months
We expect to achieve multiple value creating milestones over the next 18 months Real World Evidence Real World Evidence Secondary Endpoint 500+ patients enrolled 250+ patients @ day 90 [BT-001] First Prescription Written De Novo Submission FDA Authorization [BT-001] [BT-001] [BT-001] Q2 2022 Q3 2022
Slide 27: Next Generation Therapeutics: Using Software Instead of Drugs
Next Generation Therapeutics: Using Software Instead of Drugs A Digital Therapeutics Platform – delivering novel cognitive behavioral therapy targeting the root causes of cardiometabolic diseases Demonstrated Results– clinically meaningful results in multiple trials for Type 2 Diabetes and Hypertens
Slide 28: Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases
Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases
Better Therapeutics — Investor Presentation (May 2022) on 6ix